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Abstract. Twenty-seven polymorphisms from 12 genes have been investigated for association with tuberculosis (TB)
in up to 514 cases and 913 controls from Karonga district, northern Malawi. Homozygosity for the complement receptor
1 (CR1) Q1022H polymorphism was associated with susceptibility to TB in this population (odds ratio [OR] 3.12, 95%
Confidence interval [CI]  1.13-8.60, P = 0.028). This association was not observed among human immunodeficiency
virus (HIV)−positive TB cases, suggesting either chance association or that HIV status may influence genetic associa-
tions with TB susceptibility. Heterozygosity for a newly studied CAAA insertion/deletion polymorphism in the 3-
untranslated region of solute carrier family 11, member 1 (SLC11A1, formerly NRAMP1) was associated with protection
against TB in both HIV-positive (OR  0.70, 95% CI  0.49-0.99, P  0.046) and HIV-negative (OR  0.65, 95% CI
 0.46-0.92, P  0.014) TB cases, suggesting that the SLC11A1 protein may have a role in innate TB immune responses
that influence susceptibility even in immunocompromised individuals. However, associations of other variants of
SCLA11A with TB reported from other populations were not replicated in Malawi. Furthermore, associations with
vitamin D receptor, interferon-, and mannose-binding lectin observed elsewhere were not observed in this Karonga
study. Genetic susceptibility to TB in Africans appears polygenic. The relevant genes and variants may vary significantly
between populations, and may be affected by HIV infection status.
INTRODUCTION
Approximately eight million new cases and almost 1.8 mil-
lion deaths attributable to tuberculosis (TB) occur each year.1
In many populations, this situation is exacerbated by an in-
creasing prevalence of infection with human immunodeficien-
cy virus (HIV). Tuberculosis is caused by Mycobacterium tu-
berculosis, an intracellular pathogen that survives within mac-
rophages. It is primarily a pulmonary disease, but it may
affect organs other than the lungs, and it has been estimated
that only 10% of infected individuals develop clinical dis-
ease.2 Evidence from family, twin, and case-control studies
indicates that host genetic factors play a role in determining
the outcome of exposure and infection.3
The first convincing evidence related to HLA genes: the
HLA-DR2 molecule is associated with TB susceptibility in
some populations, while DQ1 alleles are associated in others.4
Non-HLA genes have also been implicated in TB suscepti-
bility. Variants of solute carrier family 11, member 1
(SLC11A1, formerly NRAMP1) have been associated with
TB susceptibility in populations from The Gambia, Guinea-
Conakry, Korea, Brazil and Japan.5–9 Also, evidence for link-
age of a TB susceptibility locus to a 2q35 region that contains
SLC11A1 has been reported in a Canadian Aboriginal pedi-
gree.10 A variant in the vitamin D receptor (VDR) has been
associated with TB susceptibility in The Gambia.11 There is
limited and conflicting evidence suggesting that variants in
mannose-binding lectin (MBL2) may be associated with ei-
ther protection or susceptibility to TB.12,13 Recently, an in-
terferon- (IFNG) polymorphism (+874 T/A) that may cause
increased IFNG transcription in response to NF-B has been
found to be associated with resistance to TB in Sicilians and
South Africans.14–16
The Karonga Prevention Study (KPS), a long-term epide-
miologic study of mycobacterial disease in the Karonga Dis-
trict of northern Malawi, provides an ideal opportunity to
evaluate genetic associations with TB that have been reported
from other populations, as well as to generate and investigate
new hypotheses. In recognition of this, both case control and
multicase family studies have been set up in this population to
investigate genetic risk factors for both TB and leprosy. This
paper reports on the TB case-control study. Given that HIV
is a major risk factor for TB in this population, as elsewhere
in southern Africa, and the possibility that the influence of
some genetic factors may depend upon the level of immune
competence of the host, both HIV-negative and HIV-positive
TB patients were studied.
Twenty-seven non-HLA polymorphisms from 12 genes
were investigated for association with TB susceptibility in this
population. Variants in SCL11A1, VDR, MBL2, and IFNG
were included because these genes have been associated with
TB susceptibility in other populations. Interleukin-10 (IL10)
is a key anti-inflammatory cytokine that has recently been
implicated in leprosy susceptibility in Brazil.17 Polymor-
phisms in tumor necrosis factor (TNF, formerly TNF), and
lymphotoxin alpha (LTA, formerly TNF) have been associ-
ated with leprosy susceptibility. The toll-like receptors 2 and
4 (TLR2 and TLR4) are pattern recognition molecules in-
volved in both innate and adaptive immune responses. Vari-
ants of toll receptors have recently been associated with lep-
rosy, malaria and pneumoccocal disease (Cooke G, Aucan C,
Walley AJ, Segal S and others, unpublished data).18 The
chemokine (C-C motif) ligand 3 (CCL3, formerly MIP1) was
selected as a functional candidate due to its involvement in T
helper 1 cell (TH1) differentiation. A variant in intracellular
adhesion molecule 1 (ICAM1) may be associated with sus-
ceptibility to severe malaria.17 Finally, since complement re-
ceptor 1 (CR1) can be used by M. tuberculosis to gain entry
into macrophages, it was hypothesized that some recently de-
fined variants in CR1 may influence susceptibility to myco-
bacterial disease.17
MATERIALS AND METHODS
The study protocol was reviewed and approved by the Na-
tional Health Sciences Research Committee of Malawi and by
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the Ethics Committee of the London School of Hygiene and
Tropical Medicine.
Recruitment and sample collection. The population, basic
field methods, and TB case finding and diagnostic procedures
of the KPS have been described in detail elsewhere.19,20 Tu-
berculosis cases recruited into the study were ascertained
largely by passive self-reporting at health centers, although a
small proportion were identified in the context of other stud-
ies. Sputum samples and lymph node aspirates were exam-
ined (fluorescence and Ziehl-Neelsen stain) and cultured at
project headquarters in Chilumba, with species confirmation
by the United Kingdom Public Health Laboratory Service
Mycobacterial Reference Unit (Dulwich, United Kingdom).
Biopsy specimens were sent to Professor S. Lucas (St. Thomas’
Hospital, London, United Kingdom). Inclusion in this study
required confirmation of TB by culture, smear, or histology
(excluding those whose only evidence of TB was a single
scanty smear with fewer than 10 bacilli).
Recruitment for this study began in 1996, with targets of
250 HIV-positive and 250 HIV-negative cases. Cases diag-
nosed from November 1996, together with cases diagnosed
before this and known to be HIV-negative at the time of
diagnosis (as all TB cases in Karonga have been offered HIV
counseling and testing since 1988), were included. For cases
diagnosed before 1998, up to four individually matched con-
trols were selected using project databases. Individuals were
eligible for selection as controls if they had no history or
evidence of either TB or leprosy and they were not a first- or
second-degree relative of the case to which they were being
matched. Matching criteria were age (within age groups
15−19, 20−24, 25−29, 30−34, 35−44, 45−54, 55−64, and 65
years old), sex, and area of residence (within 1 km of the
case). From 1998 a field-based method was used to identify
controls frequency-matched to cases for age (using date of
birth in 10-year calendar periods), sex, and area of resi-
dence.21 Approximately two controls were recruited for each
case. Analyses reported here include cases and controls re-
cruited up to the end of September 2001.
Cases and controls were interviewed by project paramedi-
cal staff who explained the study, provided counseling, and
invited the patients to provide a blood sample for HIV testing
and genetic analyses. Blood (7.5 mL) for HIV and genetics
testing was collected into EDTA, and placed in vaccine car-
riers with wet ice until it reached the project laboratory within
three days of collection, where cells were separated and
stored at −70°C. The DNA was separated with Nucleon kits
(Scotlab, Coatbridge, United Kingdom) following the manu-
facturer’s instructions, and shipped at 4°C to the Wellcome
Trust Centre for Human Genetics (Oxford, United Kingdom)
for analysis. Those who wished to know their HIV status were
given post-test counseling in their homes. The HIV testing
was done in duplicate using a particle agglutination test (Edg-
ware modification of Serodia; Mast Diagnositcs, Ltd., Bootle,
Merseyside, United Kingdom) and an ELISA (Vironostika
HIV Uni-form II plus 0; Organon Teknika, Ltd., Cambridge,
United Kingdom), with retesting of discordant samples.22
Genotyping. The methods used for genotyping the 27 vari-
ants investigated have been described elsewhere.17 The liga-
tion detection reaction was used to type polymorphisms in
VDR, MBL, IL10, TNF, ICAM1, CR1, and TLR4.17 The
SLC11A1, CCL3, TLR2, and LTA polymorphisms were
typed by fluorescence polymerase chain reaction (PCR) and
an amplification refractory mutation system PCR17 was used
to type the IFNG variant.
Statistical analysis. Analysis of the individually-matched
and frequency-matched studies was done separately. For the
individually-matched studies, conditional logistic regression
was used to quantify the association between disease and ge-
notype, with and without controlling for ethnic group. For the
frequency-matched study, logistic regression was used. All
analyses were stratified on HIV status of the case.
In general, HIV-negative controls were used as the com-
parison group for both HIV-negative and HIV-positive cases.
For HIV-negative cases, HIV-negative individuals are the
most valid control group. For HIV-positive cases, HIV-
positive individuals are the ideal control group. However,
relatively few HIV-positive controls were identified, and re-
stricting the control group to them would considerably limit
study power. If the genes studied are not related to the risk of
HIV infection, then it is acceptable to use HIV-negative in-
dividuals, rather than HIV-positive individuals, as the control
group for HIV-positive cases. The association between geno-
type and HIV status was thus assessed among the controls.
For the polymorphisms where there was preliminary evidence
of an association, HIV-positive controls were used as the
comparison group for HIV-positive cases.
Two estimates of effect (odds ratios [OR]) were obtained
for each polymorphism, one from the individually matched
study and one from the frequency-matched study. A summary
estimate was obtained by combining the two estimates in a
meta-analysis.
Genotyping was not always successful, and for some poly-
morphisms genotyping was attempted on only a proportion of
individuals. Thus, the number of individuals genotyped was
less than the total number of individuals who gave blood for
genetics and HIV testing.
RESULTS
Four hundred and thirty-one individuals were recruited
into the individually matched study (133 cases and 298 con-
trols). The HIV status was known for all individuals except
for one control, and DNA was obtained from 418 individuals.
A total of 1,589 individuals were recruited into the frequency-
matched case-control study (546 cases and 1,043 controls). Of
these individuals, 1,132 provided blood for testing (412 cases
and 720 controls), and 174 controls and 1 case provided a
buccal swab. Genetic data were analyzed for slightly different
numbers of individuals for each gene up to a total of 1,188
individuals. The HIV data were available for 85% of these
individuals; thus, 1,010 individuals (386 cases and 624 con-
trols) were included in the analyses.
Preliminary comparisons of genotype frequencies between
HIV-positive controls (n  82) and HIV-negative controls
(n  542) indicated that the polymorphisms TNF-238, VDR-
Bsm I, and CR1-4795 may be associated with HIV in Malaw-
ians (compare the controls in Tables 1 and 2). In each case
the rarest genotype showed a weak association (P  0.01,
0.02, and 0.04, respectively). Thus, for these polymorphisms,
HIV-positive TB cases were compared with HIV-positive
controls to assess the association between TB and genotype
(Table 1). Homozygosity for the Bsm I polymorphism in
VDR appeared to provide protection against TB among HIV-
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infected individuals (OR  0.12, 95% CI  0.04-0.4, P 
0.001). However, this association results from a high fre-
quency of the rarer homozygote (17%) in the small (n  60)
HIV-positive control group and could be a chance finding.
There was no evidence that the TNF-238 and CR1-4795 vari-
ants were associated with TB in HIV-infected individuals.
The 24 polymorphisms that did not show evidence for as-
sociation with HIV were tested for association with TB by
comparing genotype frequencies of both HIV-negative and
HIV-positive cases against those of HIV-negative controls.
Results are shown in Table 2. Among HIV-negative individu-
als, homozygosity for the CR1 variant Q1022H was associated
with TB (OR  3.12, 95% CI  1.13-8.60, P = 0.028). Evi-
dence for association with this variant was not found among
HIV-positive TB cases.
On comparing HIV-positive TB cases with HIV-negative
controls, associations were observed with MBL2 G57E het-
erozygotes (OR  1.69, 95% CI  1.04-2.75, P = 0.034), and
IL10-1082 G homozygotes (OR  0.37, 95% CI  0.18-0.76,
P = 0.007). While there was no association between either of
these variants and HIV-negative TB, the same genotype
trends were observed, suggesting that these variants may have
a subtle influence on TB susceptibility, the impact of which is
more pronounced in individuals already immunocompro-
mised by HIV infection.
There was borderline evidence that the SLC11A1 exon 2
deletion may be associated with TB susceptibility in HIV-
positive cases (OR  2.60, 95% CI  0.97-6.99, P  0.059).
Heterozygosity for the SLC11A1 CAAA polymorphism was
associated with protection in both HIV-positive (OR  0.70,
95% CI  0.49-0.99, P = 0.046) and HIV-negative (OR 
0.65, 95% CI  0.46-0.92, P = 0.014) TB cases.
DISCUSSION
In the Karonga population, heterozygosity for the 3-
untranslated (UTR) region CAAA insertion/deletion in
SCL11A1 is associated with protection against TB, regardless
of HIV status. This variant has apparently not been previ-
ously investigated for association with TB susceptibility. Fur-
thermore, an association between any SCL11A1 variant and
TB susceptibility in HIV-positive individuals has not been
described previously. That this association is observed in both
HIV-negative and HIV-positive cases suggests that the
SCL11A1 gene product acts to protect against TB even dur-
ing the immunosuppressed state of HIV infection, which may
provide insight into how SCL11A11 influences TB suscepti-
bility. The gene product is thought to act as a divalent ion
pump that can influence acidity and/or iron content of the
phagosome, and thus be involved in the direct killing of my-
cobacteria. However, it is also involved in regulation of the
development of the adaptive immune response. As the adap-
tive immune response becomes impaired by infection and de-
struction of T cells in the course of HIV infection, these find-
ings suggest SCL11A1 may be more important in the innate
immune response to TB. It is interesting to contrast this with
the growing evidence that suggests that SCL11A1 may influ-
ence development of the acquired immune response to lep-
rosy.23
It is not known whether the CAAA variant has any effect
on the function or expression of the SCL11A1 gene product.
Other SCL11A1 variants that have been associated with TB
susceptibility elsewhere (including the promoter microsatel-
lite, which does have a putative effect on the levels of
SCL11A1 expression) were not associated in this Malawi se-
ries. The association of several variants of this gene with my-
cobacterial disease is unlikely to be due to chance, but the
failure to identify a consistently associated variant may indi-
cate that other, as yet undescribed, polymorphisms in this
gene are responsible for the observed associations. A prelimi-
nary sequencing project of a 244-basepair segment of the 3-
UTR of the SLC11A1 gene in Malawians has not shown any
novel polymorphisms. An alternative possibility is that the
associations have arisen due to linkage disequilibrium with a
variant in some neighboring gene that influences TB suscep-
tibility.
There is some evidence that SCL11A1 genotype may influ-
ence susceptibility to HIV infection in Colombians.24 While
preliminary results suggest that this is not the case in Karonga
district, the possibility that the association observed in HIV-
positive cases is due to susceptibility to HIV infection rather
that TB infection cannot be ruled out.
On phagocytic cells complement receptor 1 mediates the
adherence and phagocytosis of complement-opsonized patho-
gens. Since mycobacteria use this mechanism to gain entry
TABLE 1
Genotype frequencies and odds ratios (ORs) for HIV-positive cases and HIV-positive controls*
Gene Polymorphism Genotype
HIV+ cases HIV+ controls
HIV+ cases compared to HIV+ controls OR (95% confidence limits)
P values adjusted for age, sex, zone, ethnic group% n % n
CR1 A→G at 4795 a/a 64 161 68 52
K1590E a/g 30 75 32 24 1.06 (0.59-1.92) 0.837
(McCa→McCb) g/g 6 16 0 0
252 76
TNF −238 (G→A) g/g 85 122 88 43
g/a 15 21 8 4 2.01 (0.65-6.28) 0.228
a/a 0.7 1 4 2 0.11 (0.005-2.58) 0.171
144 49
VDR C→T c/c 62 123 60 36
(Bsm I) c/t 35 69 23 14 1.65 (0.78-3.52) 0.194
(b→B) t/t 3 6 17 10 0.12 (0.04-0.40) 0.001
198 60
* Only those polymorphisms for which there was evidence that genotype was associated with HIV status are shown. HIV  human immunodeficiency virus; CR1  complement receptor 1;
TNF  tumor necrosis factor; VDR  vitamin D receptor.
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TABLE 2
Genotype frequencies for cases and controls and odds ratios (ORs)*
Gene Polymorphism Genotype
HIV+ cases HIV− cases HIV− controls HIV− cases comparedto HIV-controls:
OR (95% confidence
limits) P values
HIV+ cases compared
to HIV-controls:
OR (95% confidence
limits) P values% n % n % n
CCL3 (MIPI-) Promoter microsatellite 331/331 48 99 48 70 39 226
(TA)n at −906 331/327 24 50 27 39 28 162 0.69 (0.40-1.16) 0.156 0.74 (0.46-1.18) 0.204
331/333 18 37 15 22 19 113 0.55 (0.28-1.03) 0.062 0.65 (0.38-1.09) 0.104
Other 10 20 11 16 14 79 0.65 (0.32-1.33) 0.242 0.67 (0.35-1.28) 0.224
206 147 580
CR1 A→G at 4795 a/a 64 161 61 119 62 459
K1590E a/g 30 75 32 63 33 239 0.96 (0.65-1.42) 0.844 0.81 (0.56-1.17) 0.255
(McCa→McCb) g/g 6 16 7 13 5 36 1.75 (0.82-3.74) 0.147 1.23 (0.59-2.56) 0.588
252 195 734
G→A at 4828 g/g 46 115 50 97 48 350
R1601G g/a 40 101 38 73 42 306 0.91 (0.62-1.32) 0.609 0.96 (0.67-1.38) 0.829
(Sl1→Sl2) a/a 14 35 12 24 10 72 1.48 (0.82-2.66) 0.192 1.33 (0.77-2.32) 0.309
251 194 728
A→G at 4870 g/g 80 201 78 151 79 578
I1615V g/a 18 46 21 41 19 138 1.30 (0.84-2.01) 0.232 0.90 (0.58-1.41) 0.655
a/a 1 3 1 2 2 11 1.04 (0.20-5.23) 0.965 0.53 (0.10-2.96) 0.470
250 194 727
A→G at 3650 a/a 63 32 59 48 60 107
H1208R a/g 33 17 37 30 33 58 1.12 (0.55-2.28) 0.759 0.55 (0.18-1.65) 0.287
g/g 4 2 5 4 7 12 1.20 (0.27-5.44) 0.809 0.86 (0.08-9.30) 0.904
51 82 177
T→C at 2078 t/t 77 95 79 96 76 262
I684T t/c 13 16 13 16 15 53 0.53 (0.22-1.27) 0.155 0.88 (0.36-2.15) 0.778
c/c 10 13 7 9 9 30 0.79 (0.29-2.15) 0.644 0.86 (0.35-2.13) 0.747
124 121 345
g/g 71 164 68 133 74 496
G→T at 3093 g/t 27 62 28 55 24 160 1.45 (0.97-2.16) 0.073 1.25 (0.83-1.87) 0.290
Q1022H t/t 2 4 4 8 2 14 3.12 (1.13-8.60) 0.028 0.99 (0.26-3.76) 0.987
230 196 670
c/c 73 186 72 151 74 541
C→G at 5507 c/g 24 62 25 53 24 177 1.14 (0.76-1.68) 0.529 1.14 (0.77-1.69) 0.515
P1827R g/g 2 6 3 7 2 14 2.32 (0.84-6.37) 0.104 1.29 (0.42-3.94) 0.652
254 211 732
ICAM1 A→T at 179 K29M a/a 41 89 45 94 45 268
(ICAM-1ref→ a/t 40 86 37 78 37 222 0.96 (0.65-1.42) 0.852 0.97 (0.62-1.51) 0.890
ICAM-1Kilifi) t/t 19 42 18 37 18 106 0.97 (0.60-1.57) 0.915 0.94 (0.55-1.62) 0.827
217 209 596
IFNG Intron 1 + 874 a/a 65 154 71 151 66 467
T→A a/t 31 74 28 60 31 219 0.92 (0.63-1.32) 0.617 0.96 (0.66-1.43) 0.885
t/t 4 10 1 2 2 17 0.40 (0.08-1.84) 0.233 0.67 (0.58-4.06) 0.386
238 213 703
IL10 −592 c/c 38 94 40 85 42 297
c/a 49 120 47 98 43 301 1.02 (0.70-1.49) 0.905 1.23 (0.85-1.80) 0.274
a/a 13 32 13 27 15 107 0.91 (0.53-1.57) 0.745 0.92 (0.54-1.57) 0.758
246 210 705
−819 c/c 38 93 40 85 41 287
c/t 49 122 47 98 43 303 0.98 (0.68-1.43) 0.922 1.13 (0.78-1.65) 0.513
t/t 13 32 13 27 15 108 0.87 (0.51-1.51) 0.628 0.86 (0.51-1.48) 0.593
247 210 698
−1082 a/a 47 73 41 69 38 203
a/g 42 65 46 78 46 251 1.16 (0.76-1.76) 0.497 0.55 (0.34-0.88) 0.013
g/g 11 17 13 23 16 87 0.83 (0.46-1.50) 0.538 0.37 (0.18-0.76) 0.007
155 170 541
LTA (TNF) 5UTR microsatellite 101 absent 89 211 87 172 85 599
(AC/GT)n at −3.5 kb† 101 1 copy 10 24 13 26 15 105 0.89 (0.52-1.52) 0.658 0.64 (0.38-1.07) 0.090
101 2 copies 1 2 0 0 0.4 3
237 198 707
103 absent 66 156 62 122 62 436
103 1 copy 30 71 34 67 34 241 1.04 (0.74-1.47) 0.827 0.78 (0.55-1.11) 0.163
103 2 copies 4 10 4 9 4 30
237 198 707
105 absent 47 111 52 102 54 380
105 1 copy 43 101 40 80 39 274 1.06 (0.77-1.45) 0.728 1.12 (0.83-1.51) 0.444
105 2 copies 10 25 8 16 7 53
237 198 707
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TABLE 2
Continued
Gene Polymorphism Genotype
HIV+ cases HIV− cases HIV− controls HIV− cases comparedto HIV-controls:
OR (95% confidence
limits) P values
HIV+ cases compared
to HIV-controls:
OR (95% confidence
limits) P values% n % n % n
111 absent 94 223 95 188 94 668
111 1 copy 6 14 5 10 6 39 1.26 (0.55-2.85) 0.583 0.86 (0.41-1.78) 0.677
111 2 copies 0 0 0 0 0 0
237 198 707
MBL2 (MBP, G→A at 239 g/g 62 95 65 110 66 362
MBL) G57E g/a 34 53 31 52 29 160 1.16 (0.74-1.80) 0.522 1.69 (1.04-2.75) 0.034
(C variant) a/a 4 6 4 6 5 24 0.89 (0.31-2.52) 0.823 1.07 (0.33-3.50) 0.908
154 168 546
SLC11A1 Promoter 199/199 62 163 62 145 60 469
(NRAMP1) microsatellite (GT)n 199/201 30 79 31 71 34 266 0.88 (0.62-1.25) 0.481 0.75 (0.52-1.08) 0.123
(199  allele 3, 201/201 6 15 3 7 4 32 0.71 (0.28-1.78) 0.463 1.11 (0.51-2.40) 0.796
201  allele 2) Other 2 4 4 9 1 11
261 232 778
TGTG ins/del ins/ins 58 126 51 112 50 353
ins/del 34 74 42 91 40 287 1.01 (0.71-1.42) 0.970 0.72 (0.49-1.07) 0.108
del/del 8 17 7 15 10 69 0.68 (0.34-1.37) 0.282 0.62 (0.32-1.18) 0.147
217 218 709
CAAA ins/del del/del 50 129 49 117 42 317
ins/del 40 103 38 90 48 367 0.65 (0.46-0.92) 0.014 0.70 (0.49-0.99) 0.046
ins/ins 10 27 13 32 10 78 1.11 (0.64-1.91) 0.719 1.01 (0.57-1.79) 0.971
259 239 762
Exon 2 9 bp del ins/ins 93 152 93 155 94 493
Deletion
present 7 11 7 11 6 32 0.88 (0.38-2.02) 0.757 2.60 (0.97-6.99) 0.059
163 166 525
TLR2 Intron 2 microsat‡ 216 absent 86 215 89 192 89 658
216 1 copy 14 34 10 21 11 83 1.29 (0.72-2.32) 0.393 1.40 (0.84-2.36) 0.201
216 2 copies 0 0 1 2 0.1 1
249 215 742
222 absent 77 191 75 162 74 550
222 1 copy 21 52 23 49 25 182 0.94 (0.63-1.40) 0.763 1.04 (0.70-1.53) 0.863
222 2 copies 2 6 2 4 1 10
249 215 742
224 absent 43 106 42 90 41 304
224 1 copy 43 107 43 93 48 358 1.02 (0.76-1.37) 0.908 1.19 (0.89-1.59) 0.251
224 2 copies 14 36 15 32 11 80
249 215 742
226 absent 79 196 76 164 77 569
226 1 copy 18 46 23 49 22 166 0.96 (0.64-1.44) 0.841 1.15 (0.76-1.72) 0.507
226 2 copies 3 7 1 2 1 7
249 215 742
TLR4 Exon 4 a/a 93 112 90 146 91 389
A→G at 896 g/a 7 8 10 16 9 38 1.16 (0.58-2.31) 0.677 0.98 (0.32-3.02) 0.976
D299G g/g 0 0 0 0 0 0
120 162 427
TNF −238 g/g 85 122 90 162 87 464
g/a 15 21 10 19 13 69 0.82 (0.45-1.49) 0.515 1.37 (0.68-2.73) 0.378
a/a 0.7 1 0 0 0 0
144 181 533
−308 g/g 82 97 82 132 83 344
g/a 18 21 17 27 17 71 1.15 (0.67-1.99) 0.610 1.31 (0.59-2.90) 0.511
a/a 0 0 1 2 0.2 1 1.65 (0.10-27.78) 0.730
118 161 416
−863 c/c 82 98 78 129 72 301
a/c 17 20 20 33 26 109 0.73 (0.45-1.19) 0.204 0.59 (0.29-1.20) 0.145
a/a 1 1 2 3 2 7 2.07 (0.37-11.47) 0.407 0.71 (0.03-15.69) 0.829
119 165 417
VDR T→C 352 silent t/t 59 132 61 129 57 384
(Taq I, T→t) t/c 36 82 34 72 36 241 0.82 (0.56-1.19) 0.285 0.94 (0.64-1.38) 0.747
c/c 5 11 5 11 7 47 0.59 (0.29-1.23) 0.162 0.80 (0.36-1.78) 0.583
225 212 672
G→T t/t 49 97 48 70 53 287
(Apa I, a→A) t/g 41 82 43 63 39 210 1.36 (0.88-2.11) 0.169 1.23 (0.81-1.87) 0.322
g/g 10 20 9 13 8 46 0.98 (0.44-2.20) 0.971 1.10 (0.56-2.18) 0.783
199 146 543
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into macrophages, it was hypothesized that variants in CR1
may influence susceptibility to TB.17,25,26 Five polymorphisms
that encode amino acid substitutions in the extra-membrane
portion of the protein and which may affect either ligand
binding or CR1 stability were investigated.17 Homozygosity
for Q1022H was associated with TB susceptibility (OR 
3.12, 95% CI  1.13-8.60, P = 0.028). This variant occurs in a
ligand binding domain, close to an aspartic acid residue that is
important in C3b binding. It has been suggested that substi-
tution of glutamine to a weakly basic and more hydrophobic
histidine residue may alter ligand binding by CR1.27 If this
variant does reduce CR1 binding of C3b, it appears that
rather than providing protection by limiting M. tuberculosis
uptake, it increases TB susceptibility, indicating that uptake
via CR1 may invoke protective mechanisms. Lack of an as-
sociation between Q1022H and TB in HIV-positive individu-
als suggests that this protective mechanism is inhibited or
ablated in immunosuppressed individuals.
Interferon- is an essential and central regulator of the
human response to infection. Homozygosity for the T allele of
an intronic single nucleotide polymorphism (SNP) at +874
that may influence IFN- production is associated with sus-
ceptibility to TB in Sicilians and in South Africans.14–16 This
SNP was not associated with TB susceptibility in Malawi. This
could be because the lower allele frequency in Malawi (20%
compared with 50%) reduces the power to detect such an
association, or because the TB association is due to another
polymorphism that is in linkage disequilibrium (LD) with the
+874 SNP in Sicily but not in Malawi, or because this allele
does not affect TB susceptibility in this population. In some
populations it appears that the +874 SNP is in complete LD
with a microsatellite allele that is associated with increased
IFN- production. Genotyping of this microsatellite indicates
that while there is evidence of strong LD between it and the
+874 SNP in Malawi, this is not absolute.
The gene product of MBL2, mannose-binding lectin, binds
to mannose groups on a variety of bacteria, resulting in
complement activation and opsonophagocytosis. Three poly-
morphisms in exon 1 influence serum MBL levels. Low serum
concentrations of MBL may be associated with recurrent in-
fections in young children, and yet low producing alleles are
maintained in all populations, leading to the hypothesis that
these variants are maintained by balancing selection.17 Pro-
tection from mycobacterial infection by limiting phagocytotic
entry of mycobacteria into host cells has been proposed as a
mechanism by which such alleles may be maintained.17 There
is some evidence that such variants may be protective against
meningeal TB in Cape Coloureds but no association with
protection against pulmonary TB in The Gambia was
found.13,28 In Malawi, we found no convincing evidence of
association with TB.
Interleukin-10 is a key anti-inflammatory cytokine. Three
promoter polymorphisms (−1082, −819, −592) that may influ-
ence IL10 levels were investigated for susceptibility to TB.17
The HIV-positive, but not HIV-negative, Malawians homozy-
gous for the −1082 G allele appeared to be protected against
TB. The −1082 SNP lies in a putative transcription factor
binding site, but reports on the function of the IL10 promoter
variants are contradictory.29 The −1082 G allele has been
reported to be associated with reduced IL10 transcription, but
haplotypes bearing the G variant are usually associated with
increased IL10 levels.30,31 It is unclear how increased IL10
production would provide protection against TB. However,
there is some evidence that other, more distal IL10 promoter
polymorphisms may be more important in controlling IL10
levels than the proximal polymorphisms investigated here.32
Furthermore, one haplotype of these distal polymorphisms is
reported to be associated with increased IL10 production and
is linked to each of the three common proximal haplotypes,
perhaps explaining the variable results of studies of the proxi-
mal polymorphisms. In light of the observed −1082 G asso-
ciation, an investigation of these distal polymorphisms and
the haplotypes that are present in the Malawi population is
warranted.
Intracellular adhesion molecule 1 (ICAM1/CD54) medi-
ates both leukocyte-leukocyte and leukocyte-endothelial in-
teractions during an immune response.33An apparently del-
eterious polymorphism, K29M, which reduces binding to leu-
kocyte function associated antigen-1 and fibrinogen, two of
the key ligands for ICAM1, has been postulated to be main-
tained by balancing selection. However, there was no evi-
dence to suggest that this polymorphism influences TB sus-
ceptibility in Malawi.33
Vitamin D receptor is the receptor for the active form of
vitamin D (125(OH)2D3), which in addition to influencing
bone mass, has important immuno-modulatory effects includ-
ing suppression of cytokine synthesis, immunoglobulin pro-
duction and lymphocyte proliferation. Epidemiologic evi-
dence suggests vitamin D deficiency is associated with sus-
ceptibility to TB. There is evidence that vitamin D impedes
growth of M. tuberculosis in human macrophage and mono-
cytic cell lines, and it has been suggested that vitamin D-
containing medications may be useful in treating some forms
of leprosy.17,34 Homozygosity for a Taq 1 polymorphism (tt)
TABLE 2
Continued
Gene Polymorphism Genotype
HIV+ cases HIV− cases HIV− controls HIV− cases comparedto HIV-controls:
OR (95% confidence
limits) P values
HIV+ cases compared
to HIV-controls:
OR (95% confidence
limits) P values% n % n % n
C→T c/c 62 123 61 89 58 314
(Bsm I, b→B) c/t 35 69 37 54 35 192 1.05 (0.67-1.65) 0.824 0.85 (0.56-1.28) 0.432
t/t 3 6 3 4 7 39 0.70 (0.22-2.25) 0.546 0.64 (0.23-1.77) 0.386
198 147 545
* Statistically significant or marginally significant associations are shown in bold. HIV  human immunodeficiency virus; CCL3  chemokine (C-C motif) ligand 3; CR1  complement
receptor 1; ICAM1  intercellular adhesion molecule 1; IFNG  interferon-; IL10  interleukin 10; LTA  lymphotoxin alpha; TNF tumor necrosis factor ; UTR  untranslated region;
MBL  mannose-binding lectin; SLC11A1  solute carrier family 11, member 1; ins  insertion; del  deletion; TLR2  toll-like receptor 2; TNF  tumor necrosis factor; VDR  vitamin
D receptor.
† Baseline alleles other than 101, 103, 105, and 111.
‡ Baseline alleles other than 216, 222, 224, 226.
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in the ligand binding domain of VDR was associated with
resistance to TB in The Gambia.11 Although this genotype
was associated with susceptibility to leprosy, there was no
evidence that it influences TB susceptibility in Malawians.17
Failure to replicate the association observed in The Gambia
may indicate that VDR does not influence TB susceptibility
in Malawi, but it is also possible that the Gambian association
was due to linkage disequilibrium between the silent Taq 1
SNP in codon 352 and another polymorphism with a func-
tional effect, which does not exhibit the same LD in the
Malawi population. Among HIV infected Malawians (Table
1) homozygosity for the intronic VDR polymorphism Bsm I
(BB) appeared to be protective against TB, but this mainly
reflects a high incidence of this genotype in the small sample
of HIV-positive controls. Interestingly, the same BB geno-
type has been associated with rapid HIV disease progression
in Spaniards, but association between VDR and HIV suscep-
tibility was not assessed in that study.35
On recognition of pathogens, mammalian toll-like recep-
tors send signals to activate innate and adaptive immunity.
Both TLR2 and TLR4 can mediate cellular activation in re-
sponse to components of M. tuberculosis.36 An intronic mic-
rosatellite that may influence TLR2 expression levels has
been identified in intron 2 of the TLR2 gene but no alleles
were associated with TB susceptibility in Malawi (Segal S and
others, unpublished). A TLR4 polymorphism that results in
an amino acid substitution (Arg299Gly) in the receptor’s ex-
tra-cellular domain, and thus impairs lipolysaccharide-
induced signaling, was found not to associate with TB suscep-
tibility in Malawi.17
Tumor necrosis factor is a proinflammatory cytokine with
pleiotrophic effects. Its critical role in protection against TB is
illustrated by the observation that some patients with inflam-
matory conditions that have been treated with the anti-TNF
drug infliximab develop active TB.37 Several promoter poly-
morphisms exist that may influence TNF expression and some
have been associated with both autoimmune and infectious
diseases, although none have been associated with TB sus-
ceptibility.17,38–40 Consistent with these findings, no TNF pro-
moter polymorphisms were associated with TB susceptibility
in Malawi.
Some limited evidence that an LTA microsatellite allele
may be protective against TB in HIV-positive Malawians was
found. Like TNF, LTA is located in the HLA class III region,
and encodes a cytokine with pleiotrophic immunomodulatory
effects. Lymphotoxin alpha appears to be crucial in organiz-
ing the granulomatous response that is required for control-
ling M. tuberculosis infection in mice.41 Recently, two LTA
SNPs were shown to be associated with susceptibility to myo-
cardial infarction, and, these SNPs appear to influence the
expression and/or function of LTA.42 It would be of interest
to investigate the relationship between the upstream micro-
satellite and these putative functional polymorphisms. Any
investigation of association with TNF and LTA is complicated
by the fact that these genes lie in the HLA region and there
may be linkage disequilibrium between HLA alleles that in-
fluence TB susceptibility. There was some evidence that the
TNF-238a allele may be associated with HIV infection in
Malawi. Variants in TNF have been associated with HIV pro-
gression in some populations, but not with susceptibility.43
The chemokine (C-C motif) ligand 3, formerly known as
the macrophage inflammatory protein-1, induces activation of
macrophages and proliferation and TH1 differentiation of T
cells.44 It belongs to the C-C chemokine family and binds
receptors CCR-1, CCR-4, and CCR-5. Expression of CCL3 is
induced by M. tuberculosis infection of human alveolar mac-
rophages, with avirulent strains inducing greater expression
than virulent strains.45 There was borderline evidence that
the promoter microsatellite 333 allele might be associated
with protection against TB in HIV-negative Malawians. How-
ever, the functional effect, if any, of this promoter microsat-
ellite is unknown.
This large-scale investigation of candidate genes has shown
that genetic variants in SCLA11A1 appear to influence TB
susceptibility in Malawi, as has been found in other popula-
tions. Furthermore, this influence may extend to HIV-
infected individuals. However, the association in Malawi is
with a different variant of SCLA11A1 from that reported in
other populations, and the molecular basis of this interpopu-
lation heterogeneity requires further analysis. Previously re-
ported associations between variants of VDR, MBL, and
IFNG and TB susceptibility in HIV-negative individuals were
not replicated in this Malawian population. An association
with a novel candidate gene, CR1, was shown. This is the first
study to report analysis of genetic variants that may influence
TB susceptibility in individuals immunocompromised by HIV
infection, and we found preliminary evidence that both an
IL10 promoter variant and the Bsm I polymorphism in VDR
may influence TB susceptibility in such individuals.
Overall, this extensive analysis highlights two important
features of TB genetic susceptibility: the likely existence of
important interpopulation differences in relevant susceptibil-
ity loci and the potential for identification of false-positive
associations by analysis of variants in multiple genes. To ad-
dress both issues, future studies of polygenic susceptibility
will require larger sample sizes than generally studied to date,
as well as replication studies, ideally in both the original and
in different populations.
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